Supports clinical-enabling projects translating toward testing in humans; two-stage mechanism to derisk and then support human studies.
Eligibility Criteria:
-
Independent full-time faculty at US not-for-profit institutions with preclinical/clinical capacity.
-
As of 2025, prior ACS funding no longer required; one active MBG per PI; other ACS awards allowed if no scientific overlap.
Funding Details:
-
Stage I: up to 2 years at $135,000 direct/year + 10% IDC (max $297,000); milestone-based.
-
Stage II: up to 18 months at up to $545,000 direct + 10% IDC; must involve human testing and follow successful Stage I milestones.
-
NCE and resubmission policies apply.
Deadline:
Standard ACS electronic deadlines (June 1, December 1) unless otherwise specified by an RFA; see policies for schedule.
Where to go for further information:
-
ProposalCentral application and ACS MBG policies.